Novartis starts Phase 2 trial of MRT‑6160 for psoriatic arthritis
Novartis has begun a Phase 2a/b clinical study of MRT‑6160, a VAV1‑targeting molecular‑glue degrader, in patients with moderate to severe psoriatic arthritis. The trial is randomized, double‑blind, placebo‑controlled and multicenter. Under the global exclusive license with Monte Rosa Therapeutics, Novartis will fund and run the study, while Monte Rosa will receive a $37.5 million milestone payment and remains eligible for up to $2.1 billion in additional milestones and royalties.
Why it matters
The milestone payment provides Monte Rosa with immediate cash and the agreement gives the company exposure to a potentially large market for psoriatic arthritis treatments. Investors should note that the partnership places development risk and cost on Novartis, while Monte Rosa retains upside from future milestones and a share of U.S. profits.
Key facts
- 1Novartis initiated a Phase 2a/b trial of MRT‑6160 in active moderate to severe psoriatic arthritis. investing.com
- 2The study is a randomized, double‑blind, placebo‑controlled, multicenter design (NCT07801495). investing.com
- 3Monte Rosa Therapeutics will receive a $37.5 million milestone payment upon the first patient visit. investing.com
- 4Monte Rosa is eligible for up to $2.1 billion in development, regulatory and sales milestones under the license agreement. investing.com
- 5Novartis holds exclusive worldwide rights to develop, manufacture and commercialize MRT‑6160 and other VAV1 molecular‑glue degraders. quiverquant.com
- 6Monte Rosa will co‑fund any Phase 3 development and share 30 % of U.S. profits and losses, plus tiered royalties on ex‑U.S. net sales. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.